| Filed On | Filing |
|---|---|
| 12 Nov 2026 | SCHEDULE 13D/A |
| 12 Nov 2026 |
Form 4: Schuler Jack W, 10% owner
Bought 100,000 shares ($1M) |
| 05 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 2, 2026, it was agreed that the employment of Kieran O’Kane, Chief Commercial Officer of Biodesix, Inc. (the “Company”) would end effective November 2, 2026 (the “Separation Date”). Mr. O’Kane will be eligible for separation ... |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Delivered total revenue of $24.0 million, an increase of 10% year over year |
| 02 Oct 2026 |
Form 4: Patience John, Director
Received 1,360 shares by exercise or conversion |
| 13 Aug 2026 |
Form 4: Schuler Jack W, 10% owner
Bought 15,000 shares ($367K) |
| 12 Aug 2026 |
Form 4: Schuler Jack W, 10% owner
Bought 13,900 shares ($337K) · Bought 13,700 shares ($329K) |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; |
| 02 Jul 2026 |
Form 4: Patience John, Director
Received 1,361 shares by exercise or conversion |
| 18 Jun 2026 | SCHEDULE 13G |
| 29 May 2026 | EFFECT |
| 01 Jun 2026 | 424B3 |
| 27 May 2026 | CORRESP |
| 26 May 2026 | UPLOAD |
| 21 May 2026 | S-3 |
| 20 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Biodesix, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) on May 19, 2026. At the Annual Meeting, the Company’s stockholders voted on: (i) the election of two Class III director nominees to serve ... |
| 15 May 2026 | SCHEDULE 13G/A |
| 08 May 2026 | SCHEDULE 13G/A |
Loading...